Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated ...

FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to ...
Le Lézard

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Armata Pharmaceuticals, Inc. ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the ...